{"entity":{"id":"nct02716116","kind":"trial","name":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of TAK-788 in non-small-cell lung cancer, run by Takeda, active and no longer recruiting.","summary":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT02716116 by Takeda, with 334 participants enrolled, started 2016-06-16 and due to reach its primary completion in 2026-10-31. Interventions recorded: TAK-788.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02716116","url":"https://clinicaltrials.gov/study/NCT02716116"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02716116","phase":"1/2","setting":"A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer","sponsor":"Takeda","enrolled":334,"outcomes":[]},"route":"/trials/nct02716116/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}]}}